Indian drugmakers have had a hard time tapping into the Chinese market. But U.S. pricing pressure and China's recent policy changes aimed at further bringing down drug costs have intrigued some top Indian players.
Drugmaker Cipla’s European unit has formed a joint venture with Shanghai-based Jiangsu Acebright to manufacture respiratory products in China, marking the Indian company’s second attempt at entering the Chinese market.